Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations

Abstract Objective The studies that have extensively evaluated the relation between adipokines and metabolic parameters in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines, known to have a metabolic role, with the disease activity, metabolic status and treatment modalities. Design Data of 56 consecutive acromegalic patients (31 M and 25 F; aged 54±12years), admitted to the section of Endocrinology of the University of Palermo during the years 2005–2014, including 16 newly diagnosed untreated ( ND ), 21 during therapy with somatostatin analogues ( SA ), 12 with pegvisomant ( PE ) and 7 after surgical treatment ( SU ), grouped into uncontrolled ( group A : No. 33) and controlled ( group B : No. 23) were evaluated. Anthropometric and metabolic parameters, insulin sensitivity indexes, visceral adiposity index (VAI), leptin, soluble leptin receptor, adiponectin, visfatin, resistin, adipsin and non-esterified fatty acids (NEFAs) were assessed. In a subgroup of 21 subjects, the insulin sensitivity index (M value) derived from euglycemic clamp was calculated. Results Group A showed higher Homa-IR (p group B . ND patients showed higher VAI, triglycerides, Homa-IR, and visfatin and lower ISI Matsuda, M-value, and leptin compared to other groups (all p SA , PE and SU patients. IGF-1 (p=0.048), M-value (p=0.0029) and VAI (p=0.010) were independently associated with visfatin, while only ISI Matsuda (p=0.019) was associated with leptin. Conclusions In acromegaly visfatin could be considered a useful index of disease activity and metabolic alterations, such as insulin resistance and adipose dysfunction, regardless of the type of treatment.